Prospective Pancreatic Cancer Precision Oncology Treatment Outcomes Registry (PROCTOR)

Overview

About this study

The purpose of this study is to establish a prospective, longitudinal registry of patients with pancreatic cancer receiving clinician-directed therapy in routine practice, including FDA-approved agents used off-label or even investigational agents under a single-patient IND, in order to characterize real-world treatment patterns, effectiveness, and safety and to evaluate how clinical and tumor features, including molecular characteristics, relate to outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years at the time of consent.

  • Diagnosis of pancreatic cancer, including pancreatic ductal adenocarcinoma and other variant histologies, confirmed by pathology or by clinical/radiographic criteria documented by the treating team.

  • Receives evaluation and/or treatment for pancreatic cancer at Mayo Clinic.

  • Ability to provide informed consent and HIPAA authorization.

  • Willingness to allow collection of longitudinal clinical information from the medical record.

 

Exclusion Criteria: 

  • Age < 18 years.

  • Patient is a prisoner at the time of enrollment.

  • Inability to provide informed consent.

  • Patient declines participation or withdraws authorization for use of their data.

  • Insufficient source information to support inclusion in the final dataset (for example, inability to confirm pancreatic cancer diagnosis or inability to obtain baseline treatment/outcome information required by the registry) — this would be treated as a screen failure/not accrued rather than a consent failure.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 01/20/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kasey Boehmer, Ph.D., M.P.H.

Open for enrollment

Contact information:

Maria Mateo Chavez

5072661380

mateochavez.maria@mayo.edu

More information

Publications

Publications are currently not available